Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Kyowa Kirin Commences Japan PIII of NHE3 Inhibitor for Hyperphosphatemia
Kyowa Kirin said on April 13 that it has kicked off four Japanese PIII studies of the selective sodium-hydrogen exchanger 3 (NHE3) inhibitor tenapanor (KHK7791) for hyperphosphatemia in patients on hemodialysis and peritoneal dialysis to investigate the efficacy and safety…
To read the full story
Related Article
- Kyowa Kirin Files Hyperphosphatemia Drug in Japan
October 31, 2022
- Tenapanor Hits Mark in Japan Hyperphosphatemia Study: Kyowa Kirin
December 14, 2021
- Kyowa Kirin Gains Rights to NHE3 Inhibitor in Japan
November 29, 2017
BUSINESS
- BMS, Nikon Pitch Japan-to-Asia Cell Therapy Push, Draw Support at Policy Forum
May 21, 2026
- High-Dose Uptravi Now Available: Nippon Shinyaku
May 21, 2026
- Myelofibrosis Med Inrebic to Go on Sale June 1: Recordati Japan
May 21, 2026
- Fuji Plans July Launch for Japan’s 1st Simponi, Ranmark Biosimilars
May 21, 2026
- Sanofi Eyes Double-Digit Annual Growth for Japan Vaccine Business: Exec
May 20, 2026
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…